Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this 12-week randomized trial comparing two biologic agents known to be effective for psoriasis, ustekinumab (an interleukin-12 and interleukin-23 blocker) was more effective than etanercept (an inhibitor of tumor necrosis factor α). Adverse events associated with the two treatments were similar, but the trial was not large enough and follow-up...
Alternative Titles
Full title
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_734236256
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_734236256
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa0810652
